Company highlights

Onxeo aims to become a global leader in oncology focused on orphan diseases, supported by an attractive product pipeline:

  • Breakthrough, highly innovative products with unique mechanisms of action, in diseases with strong unmet medical needs
  • Programs with first clinical outcomes expected in the short/medium term (2018/2019)
  • Potential company changers with large partnering potential, in multi-billion dollars indications


Partnerships are key to Onxeo’s growth strategy.

Onxeo has a successful experience in licensing deals with pharmaceutical companies around the world.

The Company has already led two programmes to registration, including with the US (FDA) and European (EMA) authorities, sold or licensed four drugs and successfully executed one international merger (Topotarget, Denmark in 2014) and one acquisition (DNA Therapeutics in 2016).